F-1/A: Zhengye Biotechnology Seeks Nasdaq Listing with $8.6 Million IPO

Zhengye Biotechnology Holding Limited aims to raise capital for acquisitions and R&D through an initial public offering of 1.5 million ordinary shares, with a potential additional 225,000 shares via an underwriter option.

Summary

• Zhengye Biotechnology Holding Limited is planning an initial public offering to list its ordinary shares on the Nasdaq Capital Market.
• The company intends to offer 1,500,000 ordinary shares, with an underwriter option to purchase up to an additional 225,000 shares.
• The expected initial public offering price is between $4.00 and $5.00 per share, potentially raising up to $8.6 million if the underwriter's option is fully exercised.
• The company plans to use the net proceeds to acquire vaccine production companies and conduct research and development projects.
• Kingswood Capital Partners, LLC is acting as the underwriter for the offering.
• The offering is contingent upon Nasdaq's approval of the listing application.
• The company is subject to legal and operational risks associated with operating in China, including regulatory uncertainties and potential government intervention.
• Zhenfa Han, the director, chairman and largest shareholder, will hold approximately 91.09% of the voting power post-IPO, potentially classifying the company as a controlled company.
• The company has completed the filing procedures with the CSRC on January 8, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company is pursuing growth strategies and has competitive strengths, it also faces significant risks and challenges, including regulatory uncertainties and declining revenue.

Positives

• The company has a diverse range of veterinary vaccines.
• The company has high production quality standards.
• The company has strong research and development capabilities.
• The company has extensive distribution channels.
• The company has an experienced management team.

Negatives

• The company operates in a highly competitive market.
• The company is subject to regulatory risks associated with operating in China.
• The company's revenue decreased by 18.7% from 2022 to 2023.
• The company has high customer concentration.

Risks

• Changes in China's economic, political, or social conditions could adversely affect the company.
• Uncertainties in the interpretation and enforcement of PRC laws could limit legal protection.
• The Chinese government may intervene in the company's operations.
• Recent greater oversight by the CAC over data security could adversely impact the company.
• The company may be unable to compete effectively.
• The company may face manufacturing problems or product defects.
• The company may be subject to product liability claims.
• The company may be affected by the COVID-19 pandemic.
• The company may be unable to obtain regulatory approvals.
• The company may be adversely affected by violations of the U.S. Foreign Corrupt Practices Act.

Future Outlook

The company intends to develop its business and strengthen brand loyalty by developing high-demand products, expanding its sales and distribution network, enhancing its ability to attract and retain talented professionals, increasing investment in production lines, and increasing research and development investment.

Industry Context

The veterinary vaccine industry in China is highly competitive and rapidly evolving, with many new companies joining the competition and few leading companies. The company competes with manufacturers of veterinary vaccines, some of which have greater product development capabilities and financial, scientific, marketing, and human resources.

Comparison to Industry Standards

• According to Frost & Sullivan's analysis, Zhengye Biotechnology has the most comprehensive product portfolio among domestic veterinary vaccine companies in 2022.
• In 2022, Zhengye Biotechnology's veterinary vaccine revenue reached RMB260.3 million.
• In 2022, the annual growth rate of Zhengye Biotechnology's veterinary vaccine revenue reached 21.4%.

Related Party Transactions

• The operating entity purchased inventory from Jilin Huazheng Agriculture and Animal Husbandry Development Co., Ltd., which is controlled by Mr. Zhenfa Han.
• The operating entity sold a motor vehicle to Beijing Hanzhenyuan international hotel Co., Ltd., a company controlled by a shareholder of the Company.

Stakeholder Impact

• Shareholders will be subject to potential dilution from the issuance of new shares.
• Shareholders will be subject to the risks associated with operating in China.
• Shareholders may benefit from the company's growth strategies and potential acquisitions.
• Employees may benefit from the company's plans to attract and retain talented professionals.
• Customers may benefit from the company's plans to develop new and improved products.

Next Steps

• The company needs to obtain Nasdaq's approval for the listing application.
• The company needs to execute the underwriting agreement with Kingswood Capital Partners, LLC.
• The company needs to complete the offering and receive the net proceeds.
• The company needs to implement its plans for acquisitions and R&D.

Key Dates

Keywords

veterinary vaccines, IPO, Zhengye Biotechnology, Nasdaq, China, regulatory risks, financial performance, ordinary shares, CSRC, Kingswood Capital Partners